Posted by Michael Wonder on 24 Oct 2020
MS patients granted lifeline with ‘effective’ drug listed on PBS
24 October 2020 - Patients who develop the second progressive stage of multiple sclerosis will only have to pay $41 for a drug that helps slow down the disease with the Federal Government listing it on the Pharmaceutical Benefits Scheme.
The move will mean all patients who might benefit from “Mayzent” will only have to pay $41 per script rather than the estimated $25,000 yearly cost.
Multiple sclerosis is the most commonly acquired neurological disease in younger adults with more than 25,600 Australians living with the condition.
